Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-transplant blinatumomab maintenance for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia
jRCTs041210154Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Apr 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in acute lymphoblastic leukemia (ALL), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Study treatment completion rate and Graft-versus-host disease-free, relapse-free survival. Started Apr 2022; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041210154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041210154.